Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[41] CCR5 HIV-1 vertical transmission
Shearer, WT
Kalish, LA
Zimmerman, PA
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
[42] THE DESIGN AND SYNTHESIS OF ORALLY BIOAVAILABLE HIV-1 PROTEASE INHIBITORS
HUFF, JR
VACCA, JP
DORSEY, BD
THOMPSON, WJ
GHOSH, AK
HUNGATE, RW
LEE, HY
DARKE, PL
EMINI, EA
SCHLEIF, WA
LIN, JH
CHEN, IW
HOLLOWAY, MK
ANDERSON, PS
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 130 - 130
[43] Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization
Szabo, I
Wetzel, MA
Zhang, N
Steele, AD
Kaminsky, DE
Chen, CG
Liu-Chen, LY
Bednar, F
Henderson, EE
Howard, OMZ
Oppenheim, JJ
Rogers, TJ
JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 74 (06) : 1074 - 1082
[44] The discovery of a novel orally available CCR5 antagonist, as a therapeutic for HIV-1 infection
Nogi, Rena Nishizawa
Nishiyama, Toshihiko
Hisaichi, Katsuya
Minamoto, Chiaki
Matsunaga, Naoki
Hirai, Keisuke
Habashita, Hiromu
Takaoka, Yoshikazu
Toda, Masaaki
Takahashi, Eiji
Imawaka, Haruo
Sagawa, Kenji
Shibayama, Shiro
Fukushima, Daikichi
Maeda, Kenji
Mitsuya, Hiroaki
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[45] MEDI 242-Discovery and design of potent piperidine-based CCR5 antagonists for the potential treatment of HIV-1 infection
Chauder, Brian A.
Anderson, Donald
Aquino, Christopher J.
Bifulco, Neil
Boone, Lawrence R.
Boros, Eric E.
Chong, Pek Y.
Du, Kien S.
Duan, Maosheng
Ferris, Robert G.
Kazmierski, Wieslaw M.
Kenakin, Terrence P.
Koble, Cecilia S.
Lang, Daniel G.
Peckham, Jennifer P.
Spaltenstein, Andrew
Thompson, James B.
Youngman, Michael K.
Wheelan, Patricia J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[46] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
Berro, Reem
Sanders, Rogier W.
Lu, Min
Klasse, Per J.
Moore, John P.
PLOS PATHOGENS, 2009, 5 (08)
[47] An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site
Cohen, Carla
Forzan, Mario
Sproat, Brian
Pantophlet, Ralph
McGowan, Ian
Burton, Dennis
James, William
VIROLOGY, 2008, 381 (01) : 46 - 54
[48] Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1
Heredia, Alonso
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 124 - 124
[49] Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1
Heredia, A
Amoroso, A
Davis, C
Le, N
Reardon, E
Dominique, JK
Klingebiel, E
Gallo, RC
Redfield, RR
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) : 10411 - 10416
[50] Enhanced replication of R5 HIV-1 over X4 HIV-1 in CD4+CCR5+CXCR4+ T cells
Roy, AM
Schweighardt, B
Eckstein, LA
Goldsmith, MA
McCune, JM
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) : 267 - 275

← 1 2 3 4 5 →